Verastem stock: Q3 revenue doubles as VS-7375 advances
Published on 11/10/2026 at 13:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRevenue Growth Meets Pipeline Expansion
- Verastem reported third-quarter net product revenue of 24.0 million US dollars, supported by refill demand for AVMAPKI FAKZYNJA CO-PACK.
- The company plans to open a Phase 3 pancreatic cancer trial for VS-7375 by year-end 2026.
- An October equity offering lifted pro forma cash to 422.8 million US dollars at September 30.
Verastem reported stronger commercial revenue and continued progress for its VS-7375 oncology program in third-quarter results released Thursday, November 5, 2026. The company's stock traded at 7.71 euros on Lang & Schwarz at 13:40 CET on Tuesday, November 10, 2026.
According to the Business Wire press release published by Yahoo Finance, net product revenue reached 24.0 million US dollars for the quarter ended September 30, compared with 11.2 million US dollars a year earlier. Refill demand for the AVMAPKI FAKZYNJA CO-PACK supported sales, while fewer new patient starts, seasonal factors, commercial team changes and changing off-label use weighed on the ramp.
Pipeline Moves Toward Phase 3
Verastem said it had aligned with the U.S. Food and Drug Administration on the design of TARGET-D 301, a Phase 3 trial of VS-7375 in first-line metastatic pancreatic ductal adenocarcinoma. The company plans to open the study by the end of 2026 and expects to discuss Phase 3 designs for colorectal and non-small-cell lung cancer with the FDA before year-end.
Early data remain a central driver of the development strategy. In the company's reported cohorts, VS-7375 produced a confirmed objective response rate of 41 percent in second-line-or-later pancreatic cancer and 43 percent in second-line-or-later non-small-cell lung cancer. These results are preliminary clinical data rather than approved indications, leaving trial execution and regulatory progress as key risks for investors.
Losses Rise As Development Spending Expands
GAAP net loss narrowed to 74.7 million US dollars from 98.5 million US dollars in the prior-year quarter, helped in part by the absence of the large warrant-liability effect recorded a year earlier. The adjusted net loss widened to 72.8 million US dollars from 39.1 million US dollars, while research and development spending rose to 68.8 million US dollars as clinical and manufacturing activity expanded.
Cash, cash equivalents and investments totaled 172.8 million US dollars at quarter-end. Including gross proceeds from the October offering, pro forma cash stood at 422.8 million US dollars, which management expects to support operations into the first half of 2028 and the planned pivotal studies.
Verastem Oncology at a Glance
- Company: Verastem Oncology
- ISIN: US92337C2035
- Ticker: VSTM
- Home exchange: Nasdaq
- Lang & Schwarz price: 7.71 euros at 13:40 CET on November 10, 2026
U.S. biotechnology shares remain sensitive to clinical readouts, regulatory decisions and financing conditions; the S&P 500 market environment provides the broader equity backdrop.
